BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» No Vote At FDA Advisory Panel For Eyetech, Pfizer's Macugen
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
No Vote At FDA Advisory Panel For Eyetech, Pfizer's Macugen
Aug. 30, 2004
By
Kim Coghill
No Comments
ROCKVILLE, Md. - An FDA advisory panel Friday leaned toward favoring Macugen, a proposed treatment for age-related macular degeneration expected to have an impact on the aging Baby Boomer population. (BioWorld Today)
BioWorld